Treatment News : Peripheral Nerve Damage Remains Common Despite HIV Therapy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 13, 2011

Peripheral Nerve Damage Remains Common Despite HIV Therapy

The prevalence of a sometimes-painful nerve condition called peripheral neuropathy (PN) remains high in people with HIV despite effective antiretroviral (ARV) therapy, according to a study published in the April 24 issue of AIDS. Older age, diabetes, a low CD4 count and the use of nerve-toxic ARV drugs were the strongest predictors of developing the condition.

Earlier in the epidemic, the three most common neurological conditions in people with HIV were the development of HIV-associated dementia (HAD), infection-related neurological diseases and PN. Since the introduction of effective combination ARVs in the late 1990s, however, the rates of HAD and infection-related diseases have fallen dramatically—leaving a continued high level of PN in people with the virus.

Peripheral neuropathy occurs when the long and short nerve fibers running from the brain to the hands and feet become damaged. Some people with PN don’t have noticeable symptoms, and the only way to diagnose the disease is for a provider to test whether they have a loss of sensation in their big toes or reduced reflexes in the ankles. Others, however, can have persistent tingling sensations or sharp shooting or throbbing pain in their feet and legs.

In the early to middle years of the epidemic, the factors most commonly associated with PN were low CD4s, high viral loads, diabetes and the use of either protease inhibitors (which can reduce the body’s ability to control blood sugar) or nucleoside reverse transcriptase inhibitors (NRTIs) that damage nerve cells—most notably Zerit (stavudine) and Retrovir (zidovudine).

To determine the prevalence of PN in the modern ARV era, and the factors associated with it, Scott Evans, PhD, from the Harvard School of Public Health in Boston, and his colleagues followed 2,141 HIV-positive people between 2000 and 2007 who started ARV therapy for the first time in six different studies sponsored by the AIDS Clinical Trials Group (ACTG).

People were tested for peripheral neuropathy every 48 weeks during the seven years of the study. Eighty-one percent of the participants were men, 32 percent were black, and the average age was 39. Before starting ARV therapy, 21 percent had PN, though most—80 percent—did not have symptoms.

Evans and his colleagues found that PN not only persisted but also continued to be diagnosed, despite the fact that 82 percent of the participants got and kept their HIV levels under control after starting ARVs. Over the course of seven years, the majority who were initially diagnosed with PN had persistence of the disease, and an additional 20 percent developed neuropathy, though the vast majority continued to be without symptoms.

Evans’s team found that the factors most strongly associated with developing PN were older age, diabetes, the use of nerve-toxic NRTIs and having a CD4 count less than 200. Other factors associated with developing PN included taller height, the use of protease inhibitors and the use of statin drugs, though these associations were much weaker.

For those who developed PN while on nerve-toxic NRTIs, just over half continued to have PN and 36 percent continued to have symptomatic PN after the drugs were withdrawn. The only factor associated with recovery from PN was younger age.

Overall, the authors conclude that providers should take particular care to prevent neuropathy or to intervene, when possible, quickly when symptoms develop. Most important, they say, is to develop alternatives to nerve-toxic NRTIs in the developing world, and to watch closely for neuropathy in older people with HIV, people who start ARV therapy late or who have persistently low CD4 counts and in people who have diabetes or nutritional deficiencies.

Search: Peripheral neuropathy, neurological, neurotoxic, Zerit, stavudine, Retrovir, zidovudine, age, Scott Evans


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Hide comments

Previous Comments:


  comments 1 - 1 (of 1 total)    

Don, FORT LAUDERDALE, 2011-04-21 23:05:04
"older age" - "younger age" Please tell me what the authors' idea, with actual numbers, what is meant by those statements.

comments 1 - 1 (of 1 total)    


[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    adorableone
    New York
    New York


    Sin_Grinder
    Reno
    Nevada


    sefarady
    New York
    California


    kmfdm221
    Arcata
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you work with your doc to design your own treatment regimen?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.